US 12,221,471 B2Granted

Nanocarriers for lung inflammation therapy

AssigneeOhio State Innovation Foundation

InventorsNatalia Higuita-Castro, Daniel Gallego-Perez, Samir Ghadiali, Joshua Englert, Chandan Sen

Life of this patent

Estimating the term…

Loading patent…

Abstract

Disclosed are lung-targeted extracellular vesicles (EVs) loaded with an anti-inflammatory cargo, as well as compositions, systems, and methods for making same. The disclosed EVs can contain a lung targeted ligand, such as a fusion protein containing a lung targeting moiety. Also disclosed is a composition comprising an EV containing the disclosed fusion protein. In some embodiments, the EV is loaded with an anti-inflammatory cargo. Also disclosed is an EV-producing cell engineered to produce the disclosed EVs. Also disclosed is a method for making the disclosed EVs that involves culturing the disclosed EV-producing cells under conditions suitable to produce EVs.

Claims4

Dependent claims

An extracellular vesicle for treating Acute Respiratory Distress Syndrome (ARDS) produced by a method comprising:

i) nanotransfecting skin cells with a non-viral vector encoding a fusion protein comprising:
a) surfactant protein-A (SPA) capable of binding P63/CKAP4 or CD200 capable of binding CD200R and
b) a heterologous exosomal or lysosomal transmembrane protein under conditions suitable for extracellular vesicle secretion, and
ii) collecting the extracellular vesicles produced by the skin cells comprising the fusion protein, and wherein the extracellular vesicles are loaded with a therapeutic cargo, the heterologous exosomal protein or lysosomal transmembrane protein is inserted into the EV membrane and the SPA or CD200 protein are capable of binding P63/CKAP4 or CD200R.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 17/284,286Filed 18 Oct 2019 · us provisional application
Priority: 19 Oct 2018
Published: US 2021/0332106 A128 Oct 2021
Granted: 11 Feb 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

C07K 14/785
From animals; from humans: alveolar surfactant peptides; Pulmonary surfactant peptides
A61K 9/51
Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated…:…
A61K 31/4409
Non condensed pyridines; Hydrogenated derivatives thereof: only substituted in position 4, e.g. isoniazid, iproniazid
A61K 31/7105
Compounds having three or more nucleosides or nucleotides: natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine,…